Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor Europe
{A1EF0A44-49EE-467F-964C-F748991F5552}
+3 year(s) experience
Scrip
By Kevin Grogan 20 Nov 2019
The former GlaxoSmithKline CEO has given his views on the prospects for healthcare systems, saying that intelligently applying digital technologies can lead to simpler, more cost-effective health systems.
Topic Digital Health
Scrip
By Kevin Grogan 23 Oct 2019
Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
Scrip
By Kevin Grogan 13 Jun 2019
Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.
Topic Business strategies Strategy
Scrip
By Kevin Grogan 23 May 2019
With US drug pricing pressures and generic and biosimilar competition weighing on big pharma, new launches and brisk business in China have been providing a silver lining. Scrip writers analyze the industry landscape in light of the first-quarter results.
Topic Business strategies
Scrip
By Kevin Grogan 15 May 2019
Scrip editors will dissect Q1 sales and earnings reports of top pharma companies and focus on key trends, developments, and projected future impact.
Scrip
By Kevin Grogan 07 Mar 2019
The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.
Topic Cell and gene therapy
Scrip
By Kevin Grogan 21 Feb 2019
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.
In Vivo
04 Dec 2019
Scrip
04 Dec 2019
Scrip
29 Nov 2019
Scrip
28 Nov 2019
Scrip
26 Nov 2019
Scrip
25 Nov 2019
Scrip
19 Nov 2019
Scrip
14 Nov 2019
Scrip
13 Nov 2019
Scrip
07 Nov 2019
Scrip
06 Nov 2019
Scrip
04 Nov 2019
Scrip
01 Nov 2019
Scrip
31 Oct 2019
Scrip
30 Oct 2019
